Suven Life Sciences Ltd (Suven), Hyderabad-based biopharmaceutical company, has received four product patents, one each from Japan (4886522), Australia (2008315309), Europe (2200980) and Eurasia (16015) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2024 and 2027.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.
Venkat Jasti, CEO, Suven, said "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally.”
With these new patents, Suven has a total of five granted patents from Japan, fourteen from Australia, twelve from Europe and ten granted patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.